Research programme: small molecule therapeutics - Syntrix Biosystems

Drug Profile

Research programme: small molecule therapeutics - Syntrix Biosystems

Alternative Names: Multidrug-resistant tuberculosis therapy; SX-576; SX-682

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Syntrix Biosystems
  • Developer Syntrix Biosystems; University of Toronto
  • Class Amides; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Dihydrofolate synthetase inhibitors; Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma
  • No development reported Lung disorders; Tuberculosis

Most Recent Events

  • 16 May 2017 Syntrix Biosystems plans a phase I trial for SX 682 in combination with pembrolizumab in Melanoma (Late-stage disease, Metastatic disease, Combination therapy) in USA (NCT03161431)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Tuberculosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top